Zobrazeno 1 - 10
of 76
pro vyhledávání: '"Ken Uchibori"'
Autor:
Takahiro Akita, Ryo Ariyasu, Sho Kakuto, Keiki Miyadera, Ayu Kiritani, Ryosuke Tsugitomi, Yoshiaki Amino, Ken Uchibori, Satoru Kitazono, Noriko Yanagitani, Sadatomo Tasaka, Makoto Nishio
Publikováno v:
Thoracic Cancer, Vol 15, Iss 10, Pp 788-796 (2024)
Abstract Background It is difficult to predict gene mutations individually based on clinical background alone. Tumor markers may help to predict each gene mutation. Identifying tumor markers that can predict gene mutation will facilitate timely genet
Externí odkaz:
https://doaj.org/article/93acc07c0f8341ceb4a0c0b39dc0fe16
Autor:
Mai Suzuki, Ken Uchibori, Tomoko Oh-hara, Yumi Nomura, Ryusei Suzuki, Ai Takemoto, Mitsugu Araki, Shigeyuki Matsumoto, Yukari Sagae, Mutsuko Kukimoto-Niino, Yusuke Kawase, Mikako Shirouzu, Yasushi Okuno, Makoto Nishio, Naoya Fujita, Ryohei Katayama
Publikováno v:
npj Precision Oncology, Vol 8, Iss 1, Pp 1-13 (2024)
Abstract Brigatinib-based therapy was effective against osimertinib-resistant EGFR C797S mutants and is undergoing clinical studies. However, tumor relapse suggests additional resistance mutations might emerge. Here, we first demonstrated the binding
Externí odkaz:
https://doaj.org/article/b24524fa05214c18b25d982517bfb2eb
Autor:
Ayu Kiritani, Yoshiaki Amino, Ken Uchibori, Takahiro Akita, Yuhei Harutani, Shinsuke Ogusu, Ryosuke Tsugitomi, Ryo Manabe, Ryo Ariyasu, Satoru Kitazono, Noriko Yanagitani, Makoto Nishio
Publikováno v:
Thoracic Cancer, Vol 15, Iss 5, Pp 402-409 (2024)
Abstract Background As an epidermal growth factor receptor‐tyrosine kinase inhibitor (EGFR‐TKI), osimertinib has emerged as a standard EGFR‐mutation positive treatment for non‐small cell lung cancer (NSCLC). However, the efficacy of osimertin
Externí odkaz:
https://doaj.org/article/bf9f4e65fe294138b6c32c0d9d62d1af
Autor:
Yoshiaki Amino, Siew‐Kee Low, Hironori Ninomiya, Ayu Kiritani, Keiki Miyadera, Sho Kakuto, Takahiro Akita, Ryosuke Tsugitomi, Ryo Ariyasu, Ken Uchibori, Satoru Kitazono, Noriko Yanagitani, Makoto Nishio
Publikováno v:
Thoracic Cancer, Vol 14, Iss 33, Pp 3317-3322 (2023)
Abstract Background KRAS mutation positive lung cancer is known to be clinically characterized by older age, males, and smokers. It is reported to be more common in mucinous adenocarcinoma, but all reports are based on analysis of tissue samples. Rec
Externí odkaz:
https://doaj.org/article/65050a39348140f4a87a937f35d99782
Autor:
Ryo Ariyasu, MD, Sho Kakuto, MD, Keiki Miyadera, MD, Takahiro Akita, MD, Ayu Kiritani, MD, Ryosuke Tsugitomi, MD, Yoshiaki Amino, MD, Ken Uchibori, MD, PhD, Satoru Kitazono, MD, PhD, Noriko Yanagitani, MD, PhD, Makoto Nishio, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 6, Pp 100524- (2023)
Introduction: Only a few reports have determined whether recently advanced anticancer drugs, particularly next-generation tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs), prolong the survival of patients with NSCLC in the re
Externí odkaz:
https://doaj.org/article/461d74d1b3d4494e8199e62cc0a7c7d3
Autor:
Hiroyuki Sakashita, Ken Uchibori, Yasuto Jin, Toshiharu Tsutsui, Takayuki Honda, Rie Sakakibara, Takahiro Mitsumura, Yoshihisa Nukui, Tsuyoshi Shirai, Masahiro Masuo, Kozo Suhara, Haruhiko Furusawa, Takaaki Yamashita, Takehiko Ohba, Kazuhito Saito, Jun Takagiwa, Yoshihiro Miyashita, Naohiko Inase, Yasunari Miyazaki
Publikováno v:
Thoracic Cancer, Vol 13, Iss 9, Pp 1267-1275 (2022)
Abstract Background A standard treatment regimen for advanced non‐small cell lung cancer (NSCLC) patients with interstitial lung disease (ILD) has not been established since most clinical trials exclude such patients because of the high risk of acu
Externí odkaz:
https://doaj.org/article/fe5bbcf9dbb64b87b0926aa52b897ff9
Autor:
Yuki Shimizu, Koutaroh Okada, Jun Adachi, Yuichi Abe, Ryohei Narumi, Ken Uchibori, Noriko Yanagitani, Sumie Koike, Satoshi Takagi, Makoto Nishio, Naoya Fujita, Ryohei Katayama
Publikováno v:
npj Precision Oncology, Vol 6, Iss 1, Pp 1-13 (2022)
Abstract Anaplastic lymphoma kinase (ALK) fusion is found in ~3%–5% of patients with non-small-cell lung cancers (NSCLCs). Although the third-generation ALK tyrosine kinase inhibitor (TKI) lorlatinib shows high clinical efficacy in ALK-positive NSC
Externí odkaz:
https://doaj.org/article/c2a1926a23da4e888e277aae73418fe6
Autor:
Takahiro Yoshizawa, Ken Uchibori, Mitsugu Araki, Shigeyuki Matsumoto, Biao Ma, Ryo Kanada, Yosuke Seto, Tomoko Oh-hara, Sumie Koike, Ryo Ariyasu, Satoru Kitazono, Hironori Ninomiya, Kengo Takeuchi, Noriko Yanagitani, Satoshi Takagi, Kazuma Kishi, Naoya Fujita, Yasushi Okuno, Makoto Nishio, Ryohei Katayama
Publikováno v:
npj Precision Oncology, Vol 5, Iss 1, Pp 1-11 (2021)
Abstract Approximately 15–30% of patients with lung cancer harbor mutations in the EGFR gene. Major EGFR mutations (>90% of EGFR-mutated lung cancer) are highly sensitive to EGFR tyrosine kinase inhibitors (TKIs). Many uncommon EGFR mutations have
Externí odkaz:
https://doaj.org/article/c1c4f342481c4dad8da1ff3a202ae813
Clinical influence of switching companion diagnostic tests for EGFR‐TKs from Therascreen to Cobas v2
Autor:
Ken Uchibori, Natsuki Takano, Ryo Manabe, Ryosuke Tsugitomi, Shinsuke Ogusu, Takehiro Tozuka, Hiroaki Sakamoto, Hiroshi Yoshida, Yoshiaki Amino, Ryo Ariyasu, Satoru Kitazono, Noriko Yanagitani, Makoto Nishio
Publikováno v:
Thoracic Cancer, Vol 12, Iss 6, Pp 906-913 (2021)
Abstract Background Several companion diagnostic (CDx) tests for epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) have been approved. In our institute, the CDx test for EGFR‐TKIs was changed from the Therascreen test (Thera
Externí odkaz:
https://doaj.org/article/59e40e267c2d484f9b71094fb6334be9
Feasibility of next‐generation sequencing test for patients with advanced NSCLC in clinical practice
Autor:
Ryo Ariyasu, Ken Uchibori, Hironori Ninomiya, Shinsuke Ogusu, Ryosuke Tsugitomi, Ryo Manabe, Hiroaki Sakamaoto, Takehiro Tozuka, Hiroshi Yoshida, Yoshiaki Amino, Satoru Kitazono, Noriko Yanagitani, Kengo Takeuchi, Makoto Nishio
Publikováno v:
Thoracic Cancer, Vol 12, Iss 4, Pp 504-511 (2021)
Abstract Background The usefulness of the Oncomine Dx Target test (Oncomine Dx), a next‐generation sequencing (NGS) test, has already been proven in clinical trials. However, NGS requires high‐quality tumor samples and takes a long time to genera
Externí odkaz:
https://doaj.org/article/7b7ef5a8795d4eb2b4b8ec0478f05a2a